The RxWise device offers people with diabetes a safety check system to help avoid potentially dangerous adverse drug reactions.

Test Your Knowledge Issue 306

This Weeks Cartoon by Theresa L. Garnero, ARNP, CDE. Issue 306

Glufast, which is close to market is an insulin secretagogue with a rapid onset and short duration of action, lowers post-meal glucose levels by improving the body's own ability to produce insulin.

After successfully demonstrating that a groundbreaking treatment strategy can reverse type 1 diabetes in animal studies, the FDA has given the go-ahead for researchers from the University of Pittsburgh Medical Center to begin a phase I trial...

The body's ability to heal even small skin wounds normally slows down as we age. But a new study in older adults finds that regular exercise may speed up the wound-healing process by as much as 25 percent.

Investigators have found that about 25 percent of patients with diabetes have symptoms of depression, confirming the relationship between these two conditions.

The combination of morphine and gabapentin achieves better analgesia for neuropathic pain than each drug alone, according to the results of a randomized trial.

In patients taking metformin as monotherapy to treat type 2 diabetes, achieving a low level of glycosylated hemoglobin level (HbA1c) during the first year predicts a longer period of effectiveness for the medication, investigators report.

Statins, beta blockers, aspirin and angiotensin-cardioverting enzyme (ACE) inhibitors all decrease mortality in patients with peripheral artery disease (PAD), investigators report.

FDA’s Approval of Continuous Glucose Sensor Accelerates Development of Artificial Pancreas The approval of the 2nd CGMS into the market place will push forward research on the closed loop artificial pancreas.

Measurement of the ankle/brachial index (ABI) is a simple way of identifying patients with diabetes who are at increased risk of future cardiovascular disease.

Clinical studies show significant blood sugar reductions (HbA1c) sustained for one year - Trials also show no association with weight gain; overall incidence of side effects, including hypoglycemia and edema, similar to placebo - Regulatory submission...

A new study released in the scientific journal Nutrition & Metabolism found that type 2 diabetes can be managed and controlled simply by minor changes in the diet alone without the need for weight loss or the use of insulin medications.

Empire Study: Effects of Rosiglitazone + Submaximal Doses of Metformin Verses Increasing Does of Metromin in Type 2 DiabetesAddition of Rosiglitazone to submaximal doses of MET may be a suitable alternative to the maximal effective dose of MET...

Mitiglinide plus insulin glargine combination therapy is useful for lowering both fasting and postprandial hyperglycemia in a subpopulation of type 2 diabetes.

Obese and overweight individuals suffering Type 2 diabetes showed significant health improvements after only three weeks of diet and moderate exercise even though the participants remained overweight.

Physicians and educators should be also targeting postprandial regulation, which has been shown to improve glucose control and to reduce the progression of atherosclerosis and CV events.